Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

Launched by DHAKA MEDICAL COLLEGE · Apr 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments for patients with severe Hemophilia A, a condition that makes it hard for blood to clot and can lead to excessive bleeding. The study aims to compare the effects of low doses of a medication called Emicizumab with low doses of Factor VIII, which is a common treatment for this condition. The goal is to find out if the lower dose of Emicizumab is just as effective as the low dose of Factor VIII, while also being more cost-effective. This is important because standard doses of Emicizumab can be very expensive, making it difficult for patients and healthcare systems to manage.

To participate in the trial, individuals must have severe Hemophilia A, either with or without a specific complication known as an inhibitor to Factor VIII. The study will involve 20 patients who will receive treatment for six months, and researchers will closely monitor their bleeding rates and overall health. Importantly, this trial also aims to ensure that patients can receive effective treatment without financial strain, while maintaining their health and safety throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Severe hemophilia A patient with or without inhibitor to factor VIII.
• Exclusion Criteria:
• • 1. Severe hemophilia A patient not willing to participate.